A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols

Vaccine

Volumn 27, Issue 10, 2009, Pages 1557-1565

  Lundberg, Kajsa ^a   Roos, Anna Karin ^a   Pavlenko, Maxim ^a   Leder, Christoph ^b   Wehrum, Diana ^a   Guevara Patiño, José ^c   Andersen, Rikke Sick ^d   Pisa, Pavel ^a  

^a Immune and Gene Therapy Laboratory   (Sweden)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Monitoring; Peptides; Prostate specific antigen; T cells; Vaccination

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; PEPTIDE DERIVATIVE; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN 53 61 PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DNA TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PLASMIDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 60649083935     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.01.011     Document Type: Article

References (38)

1. De Petris L., Bergfeldt K., Hising C., Lundqvist A., Tholander B., Pisa P., et al. Correlation between HLA-A2 gene frequency, latitude, ovarian and prostate cancer mortality rates. Med Oncol 21 (2004) 49-52
2. Xue B.H., Zhang Y., Sosman J.A., and Peace D.J. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 30 (1997) 73-78
3. Chakraborty N.G., Stevens R.L., Mehrotra S., Laska E., Taxel P., Sporn J.R., et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 52 (2003) 497-505
4. Alexander R.B., Brady F., Leffell M.S., Tsai V., and Celis E. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 51 (1998) 150-157
5. Perambakam S., Xue B.H., Sosman J.A., and Peace D.J. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 51 (2002) 263-270
6. Correale P., Walmsley K., Nieroda C., Zaremba S., Zhu M., Schlom J., et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89 (1997) 293-300
7. Eder J.P., Kantoff P.W., Roper K., Xu G.X., Bubley G.J., Boyden J., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6 (2000) 1632-1638
8. Barrou B., Benoit G., Ouldkaci M., Cussenot O., Salcedo M., Agrawal S., et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53 (2004) 453-460
9. Pavlenko M., Roos A.K., Leder C., Hansson L.O., Kiessling R., Levitskaya E., et al. Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother 53 (2004) 1085-1092
10. Roos A.K., Pavlenko M., Charo J., Egevad L., and Pisa P. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 62 (2005) 217-223
11. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91 (2004) 688-694
12. Miller A.M., Ozenci V., Kiessling R., and Pisa P. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother 28 (2005) 389-395
13. Elkord E., Williams P.E., Kynaston H., and Rowbottom A.W. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer. Int Immunol 17 (2005) 1315-1325
14. Gold J.S., Ferrone C.R., Guevara-Patino J.A., Hawkins W.G., Dyall R., Engelhorn M.E., et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 170 (2003) 5188-5194
15. Terasawa H., Tsang K.Y., Gulley J., Arlen P., and Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res 8 (2002) 41-53
16. Keilholz U., Martus P., and Scheibenbogen C. Immune monitoring of T-cell responses in cancer vaccine development. Clin Cancer Res 12 (2006) 2346-2352
17. Britten C.M., Gouttefangeas C., Welters M.J., Pawelec G., Koch S., Ottensmeier C., et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57 (2008) 289-302
18. Janetzki S., Panageas K.S., Ben-Porat L., Boyer J., Britten C.M., Clay T.M., et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 57 (2008) 303-315
19. Zeh III H.J., Leder G.H., Lotze M.T., Salter R.D., Tector M., Stuber G., et al. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 39 (1994) 79-86
20. Elvin J., Potter C., Elliott T., Cerundolo V., and Townsend A. A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity. J Immunol Methods 158 (1993) 161-171
21. Andersen M.H., Tan L., Sondergaard I., Zeuthen J., Elliott T., and Haurum J.S. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55 (2000) 519-531
22. Lundwall A., and Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214 (1987) 317-322
23. Houghton C.S., Engelhorn M.E., Liu C., Song D., Gregor P., and Livingston P.O. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 25 (2007) 5330-5342
24. Firat H., Garcia-Pons F., Tourdot S., Pascolo S., Scardino A., Garcia Z., et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol 29 (1999) 3112-3121
25. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 185 (1997) 2043-2051
26. Roos A.K., Moreno S., Leder C., Pavlenko M., King A., and Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 13 (2006) 320-327
27. Pavlenko M., Leder C., Roos A.K., Levitsky V., and Pisa P. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate 64 (2005) 50-59
28. Alves P.M., Faure O., Graff-Dubois S., Cornet S., Bolonakis I., Gross D.A., et al. STEAP, a prostate tumor antigen, is a target of human CD8(+) T cells. Cancer Immunol Immunother 55 (2006) 1515-1523
29. Rice J., Dunn S., Piper K., Buchan S.L., Moss P.A., and Stevenson F.K. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. Cancer Res 66 (2006) 5436-5442
30. Han J.F., Zhao T.T., Liu H.L., Lin Z.H., Wang H.M., Ruan Z.H., et al. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28. Cancer Immunol Immunother 55 (2006) 1575-1583
31. Oh S., Terabe M., Pendleton C.D., Bhattacharyya A., Bera T.K., Epel M., et al. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. Cancer Res 64 (2004) 2610-2618
32. Hu N., D'Souza C., Cheung H., Lang H., Cheuk E., and Chamberlain J.W. Highly conserved pattern of recognition of influenza A wild-type and variant CD8+ CTL epitopes in HLA-A2+ humans and transgenic HLA-A2+/H2 class I-deficient mice. Vaccine 23 (2005) 5231-5244
33. Kaufman H.L., Wang W., Manola J., DiPaola R.S., Ko Y.J., Sweeney C., et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22 (2004) 2122-2132
34. Gulley J.L., Arlen P.M., Bastian A., Morin S., Marte J., Beetham P., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11 (2005) 3353-3362
35. Forsberg O., Carlsson B., Malmstrom P.U., Ullenhag G., Totterman T.H., and Essand M. High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate 69 (2008) 70-81
36. Marshall D.J., San Mateo L.R., Rudnick K.A., McCarthy S.G., Harris M.C., McCauley C., et al. Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine. Cancer Immunol Immunother 54 (2005) 1082-1094
37. Gregor P.D., Wolchok J.D., Turaga V., Latouche J.B., Sadelain M., Bacich D., et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 116 (2005) 415-421
38. Johnson L.E., Frye T.P., Arnot A.R., Marquette C., Couture L.A., Gendron-Fitzpatrick A., et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 24 (2006) 293-303